A drug based on the plasma of COVID patients passed clinical trials – RBK

Photo: Denis Grishkin / AGN “Moscow”

The drug “Covid-globulin” has passed clinical trials and received a permanent registration certificate from the Ministry of Health of Russia. About it informs Rostec, whose subsidiary holding, Natsimbio, produces the drug.

“The world’s first drug of a specific anticoid immunoglobulin has successfully passed the final two phases of clinical trials, proving its safety and effectiveness,” said Sergei Chemezov, CEO of the state corporation.

“Covid Globulin” contains antibodies to COVID-19, which were obtained from the blood plasma of people who had been ill. The antibodies that make up the drug can neutralize the currently circulating strains of the coronavirus.

According to the results of a double-blind, placebo-controlled comparative study, in 7 out of 10 patients who were treated with “COVID-globulin” as part of complex therapy, there was a decrease in the risk of the disease becoming more severe. The greatest effectiveness of “Covid-globulin” was manifested when used in the early stages of the disease, the state corporation said in a statement.

The drug was developed and produced by the research and production association “Microgen”, which is part of the “Natsimbio” holding.


Bir yanıt yazın